This announcement is a separate document:
東瑞製藥：有關合營公司的最新進展-Ebronucimab（PCSK9抑制劑）在中國治療高危或極高危高膽固醇血癥的IIb期臨床試驗提前完成患者入組
DAWNRAYS PHARMA: UPDATE ON JOINT VENTURE COMPANY-EARLY COMPLETION OF PATIENT ENROLLMENT IN PHASE IIB CLINICAL TRIAL FOR EBRONUCIMAB (PCSK9 INHIBITORS) FOR TREATING PATIENTS SUFFERING FROM HIGH- OR VERY HIGH-RISK HYPERCHOLESTEROLEMIA IN THE PRC
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.